Table 3.
PHARMetrics | GE | |||
Native | Transformed | Native | Transformed | |
Total persons | 32818355 | 10278445 | ||
Drug aggregation | ||||
Total Drug Eras | 718590080 | 309797580 | 231492741 | 96614637 |
Eras per person | 21.90 | 9.44 | 22.52 | 9.4 |
Average exposure length | 31 days | 79 days | NA | 108 days |
Rofecoxib | ||||
Total persons | 349929 | 186763 | ||
Total rofecoxib Eras | 1423273 | 510078 | 652234 | 264654 |
Eras per person | 4.07 | 1.46 | 3.49 | 1.42 |
Average exposure length | 34 days | 99 days | NA | 102 days |
Condition aggregation | ||||
Total Condition Eras | 3627194305 | 804977267 | 81693914 | 61795940 |
Eras per person | 110.52 | 24.53 | 7.95 | 6.01 |
Average Condition Era length | NA | 6 days | NA | 88 days |
Acute myocardial infarction (AMI) | ||||
Total persons | 221437 | 53063 | ||
Total AMI Eras | 5547711 | 292980 | 85940 | 53290 |
AMI Eras per person | 25.05 | 1.32 | 1.62 | 1.00 |
Average Condition Era length | NA | 11 days | NA | 175 days |